What is CYRX's health score?

Cryoport, Inc. (CYRX) has a TradeApes health score of 43 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is CYRX's estimated fair value?

Based on our 5-year discounted cash flow model, Cryoport, Inc.'s estimated fair value is $20.93 per share, representing a 33.4% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is CYRX undervalued or overvalued?

Our model currently rates CYRX as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for CYRX... Refresh in a moment for the full analysis.

Cryoport, Inc. (CYRX)

Healthcare Undervalued low weak

$15.69

Updated: 2026-05-30

TradeApes Score

Financial Strength

30 Weak

Operating Trend

40 Weak

Relative Value

50 Mixed

Capital Allocation

50 Mixed

Risk

50 Mixed

Est. Fair Value $20.93

DCF Upside +33.4%

Sector Rank #988 of 6597

Key Findings

+ Low P/E — below 12×, potential value relative to earnings

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.